Sarepta Share Price Doubles Since Benzinga Broke News of Dr. Farkas' FDA Departure
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) shot up this week as the FDA announced an accelerated approval of the company’s treatment for Duchenne Muscular Dystrophy, Eteplirsen.
Sarepta’s star continued to shine brightly as the company announced pricing for its drug Monday night.
Traders and investors could have seen this coming as early as the evening of September 13 by following news on the Benzinga Pro platform. Benzinga analysts were first to confirm Twitter reports that a regulator opposed to Sarepta’s treatment had left the agency.
Since that initial report, the company’s share price has more than doubled. It sat at $56.47 at press time, from $25.60 at the time of that initial report.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.